 |
|
|
|
February 2007 Cover
|
|
The US Food and Drug Administration (FDA) has approved the use of a new, temporary facial filler to correct the symptoms of facial lipoatrophy in HIV-infected patients. The filler,
known by the brand name Radiesse, consists of synthetic calcium hydroxylapatite suspended in a gel carrier, and is injected into the skin. It is already approved for use as a tissue marker, for
the treatment of vocal-fold insufficiency, and to correct certain dental defects, according to an FDA release.
A 100-patient study found statistically significant improvements in cheek thickness through six months in HIV-infected patients with facial lipoatrophy; the majority of patients received
a total of three injections during the study period: one at baseline, a second at one month, and a touch-up at six months.
from
theBodyPro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
